Clinical Trial Update: Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial in adults 18-49 is evaluating two vaccine formulations encoding the RSV monovalent antigen or the influenza A(H5) antigen; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Influenza A(H5) Monovalent Antigen Vaccine (Sanofi) (Influenza A(H5) monovalent antigen vaccine)
• RSV Monovalent Antigen Vaccine (Sanofi) (RSV monovalent antigen vaccine)

Snippet

Sponsor: Sanofi | Conditions: Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | Phase 1 | Status: NOT_YET_RECRUITING